Pure Global AI
NCT06364072Not yet recruiting

Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients

Open-label, Prospective Study to Assess the Safety, Tolerability, Analgesic Effect and Feasibility of Intranasal Sufentanil/Ketamine in Pediatric Patients With Moderate or Severe Pain, in an Acute Care Setting
Cessatech A/SPhase 2/3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Pain
Drug/Device/Intervention
CT001
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Cessatech A/S
Timeline & enrollment
Phase
Phase 2/3
Start date
Apr 15, 2024
End date
Sep 20, 2024
Enrollment
150 participants
Primary outcome

To assess the safety and tolerability,To evaluate the analgesic effect

Summary

The proposed study aims to investigate the safety, tolerability, analgesic efficacy, and
 feasibility of intranasal sufentanil/ketamine (CT001) in pediatric participants attending an
 acute care (i.e. emergency) setting. The study is a part of the clinical development plan for
 the development of CT001 nasal spray for treatment of acute pain in children.

ICD-10 classifications
Pain, unspecifiedPain, not elsewhere classifiedPain in limbAcute painOther chronic pain
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06364072
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06364072 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Cessatech A/S and is currently Not yet recruiting. The study focuses on Pain. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.